High-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for men with intermediate or high risk prostate cancer: Analysis of short- and medium-term urinary toxicity and biochemical control

International Journal of Clinical and Experimental Medicine

Volumn 4, Issue 1, 2011, Pages 43-52

  Pellizzon, Antonio Cassio Assis ^a,b,c   Fogaroli, Ricardo Cesar ^a,b   Silva, Maria Leticia Gobo ^a   Castro, Douglas Guedes ^a,c   Maia, Maria Conte ^a   Lopes, Ademar ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b Radiation Oncology Service   (Brazil)

^c HOSPITAL ALEMÃO OSWALDO CRUZ   (Brazil)

Author keywords

Biochemical control; Brachytherapy; Prostate cancer; Radiotherapy; Toxicity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BRACHYTHERAPY; BRAZIL; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; CYSTITIS; DISEASE SEVERITY; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; FEASIBILITY STUDY; FOLLOW UP; HEMATURIA; HUMAN; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; RADIATION DOSE FRACTIONATION; URINARY FREQUENCY; UROGENITAL TRACT DISEASE;

EID: 79951685562     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59:225-249.
2. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002; 53:1097-1105.
3. Zelefsky, M. J., Chan, H., Hunt, M., Yamada, Y., Shippy, A. M., Amols, H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006; 176: 1415-1419.
4. Kupelian PA, Mohan DS, Lyons J, Klein EA, Reddy CA. Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 46:567-574.
5. Fowler, JF. The radiobiology of prostate cancer including new 8. aspects of fractionated radiotherapy. Acta Oncol 2005; 44: 265-276.
6. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late -responding normal tissue. Int J Radiat Oncol Biol Phys 2002; 52:6-13.
7. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, Pfeffer R, Cutajar CL, Van der Kwast T, Collette L. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. Lancet Oncol. 2010; 11:1066-1073.
8. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU; Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21:3972-3978.
9. Pellizzon ACA, Salvajoli JV, Maia MAC, Ferrigno R, Novaes PE, Fogarolli RC, Pellizzon RJ. Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer. J Urol 2004;171:1105-1108.
10. Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:380-385.
11. Pellizzon AC, Salvajoli J, Novaes P, Maia M, Fogaroli R, Gides D, Horriot R. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition. Int J Med Sci 2008; 5:113-120.
12. Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 2004; 100(3):538-543.
13. Viani GA, Stefano EJ, Afonso SL. Higher-thanconventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009; 74:1405-1418.
14. Martinez A, Gonzalez J, Spencer W, Gustafson G, Kestin L, Kearney D, Vicini FA. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol. 2003;169:974-979;
15. Viani GA, Pellizzon AC, Guimarães FS, Jacinto AA, dos Santos Novaes PE, Salvajoli JV. High dose rate and external beam radiotherapy in locally advanced prostate cancer. Am J Clin Oncol. 2009;32:187-190.
16. Hsu IC, Bae K, Shinohara K, Pouliot J, Purdy J, Ibbott G, Speight J, Vigneault E, Ivker R, Sandler H. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys. 2010;78:751-8
17. Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H, Brundage M, Kwan W. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005; 23:6132-6138.
18. Higgins GS, McLaren DB, Kerr GR, Elliott T, Howard GC. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 2006; 65: 982-989.
19. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensitymodulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007; 68:1424-1430.
20. Yeoh EE, Holloway RH, Fraser RJ, Botten RJ, Di Matteo AC, Butters J, Weerasinghe S, Abeysinghe P. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 2006; 66:1072-1083.
21. Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Konski AA, Movsas B, Greenberg RE, Uzzo RG, Ma CM, McNeeley SW, Buyyounouski MK, Price RA Jr. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006; 64:518-526.
22. Benoit RM, Naslund MJ, Cohen JK. Complications after radical retropubic prostatectomy in the Medicare population. Urology 2000; 56:116-120.
23. Fröhlich G, Agoston P, Lövey J, Polgár C, Major T. The effect of needle number on the quality of high-dose-rate prostate brachytherapy implants. Pathol Oncol Res 2010;16:593-599.
24. Varkarakis J, Bartsch G, Horninger W. Longterm morbidity and mortality of transurethral prostatectomy: a 10 year follow-up. Prostate 2004; 58:248-251.
25. Sullivan L, Williams SG, Tai KH, Foroudi F, Cleeve L, Duchesne GM. Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother Oncol. 2009; 91(2):232-236.
26. Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004; 171:1098-1104.
27. Morton GC, Loblaw DA, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Keller B, Danjoux C, Szumacher E, Thomas G. Singlefraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life. Int J Radiat Oncol Biol Phys 2010; 77:811-817.
28. Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys 2005; 62:1322-1331.
29. Martinez A, Galalae R, Gonzalez J, Mitchell C, Gustafson G, Kovacs G. No apparent benefit at 5 years from a course of neoadjuvant/ concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose. J Urol 2003; 170: 2296-2301.